Abstract: The present invention relates to a composition comprising a supernatant of a peripheral blood mononuclear cell (PBMC) cell culture for use in the treatment or prevention of an allergy or an allergic reaction caused by the administration of at least one food and/or inhalation allergen or by the systemic administration of at least one drug to a human or mammal body.

Abstract: The present invention relates to a method for determining the potency of a supernatant of a mammalian cell culture to be used in the treatment of an inflammatory condition.

Abstract: The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

Abstract: The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

Abstract: The present invention relates to a method for determining the potency of a supernatant of a mammalian cell culture to be used in the treatment of an inflammatory condition.

Abstract: The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

Abstract: The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

Abstract: The present invention relates to a method for discriminating between early and advanced stage lung carcinoma in an individual suffering from lung carcinoma comprising the steps of a) providing a sample of an individual suffering from lung carcinoma, b) determining the level of heat shock protein 27 (HSP27) in said sample, c) comparing the determined level of HSP27 in said sample with a reference range of HSP27 measured in samples of control individuals with an early stage lung carcinoma and/or with advanced stage lung carcinoma, d) diagnosing early stage lung carcinoma in said individual when the level of HSP27 in sample a) is below the reference range of HSP27 in samples of control individuals with advanced stage lung carcinoma or within the reference range of control individuals with early stage lung carcinoma and diagnosing advanced stage lung carcinoma when the level of HSP27 in sample a) is above the reference range of HSP27 in samples of control individuals with early stage lung carcinoma or within the

Abstract: The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

Abstract: The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

Abstract: Method for diagnosing a cardiovascular disease in an individual comprising the steps of: providing a sample of an individual; determining the amount of cytokeratin-18 (CK-18) or fragments thereof and/or interleukin-1? precursor (IL-1? precursor) in said sample; comparing the amount of CK-18 or fragments thereof and/or IL-1? precursor in said sample to the amount of CK-18 or fragments thereof and/or IL-1? precursor present in a reference control of at least one individual not suffering from a cardiovascular disease; and diagnosing a cardiovascular disease if the amount of CK-18 or fragments thereof in the sample is increased in comparison to the amount of CK-18 or fragments thereof in the reference control and/or the amount of IL-1? precursor in the sample is decreased in comparison to the amount of IL-1? precursor in the reference control.

Abstract: A process for the continuous conversion of energy chemically bound in a starting fuel based on C-H compounds into usable mechanical energy. For this purpose, a gas turbine is used and in order to obtain high mechanical efficiency the combustion is effected at least partially with a fuel obtained from the starting fuel by endothermic reaction, the heating of the reaction space for the endothermic reaction being effected either by compressed combustion air, which has been heated by the exhaust gases, or by the hot exhaust gas itself.